News Breaks |
|
|
| October 22, 2012 |
| 06:56 EDT |  | S, SRPT | Stocks with implied volatility below IV index mean; SRPT S
Stocks with implied volatility below IV index mean; Sarepta (SRPT), Sprint (S) according to iVolatility. |
|
|
News For S;SRPT From The Last 14 Days Check below for free stories on S;SRPT the last two weeks. |
|
|
| June 19, 2013 |
| 16:26 EDT |  | S | On The Fly: Closing Wrap
 Subscribe for More Information |
|
| 12:09 EDT | | S | On The Fly: Midday Wrap
Subscribe for More Information |
|
| 12:06 EDT | | S | Options with decreasing implied volatility: DISH VRTX SUPN S
Subscribe for More Information |
|
| 11:13 EDT |  | SRPT | Sarepta rises after reporting clinical data
Subscribe for More Information |
|
| 10:25 EDT |  | S | Sprint shares worth $7.51 under SoftBank deal, says Janco
Janco calculates that current Sprint shareholders will receive $7.51 per share upon the closing of the deal with SoftBank, which the firm expects to happen on Tuesday, June 25. The firm views upside to $7.51 from current levels as attractive and keeps a Buy rating on Sprint shares. |
|
| 10:01 EDT |  | S | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 09:54 EDT | | SRPT | Sarepta data supports accelerated approval, says Piper Jaffray
Subscribe for More Information |
|
| 09:24 EDT | | S | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 08:44 EDT | | S | Sprint acquisition by SoftBank likely to be approved, says Wells Fargo
Subscribe for More Information |
|
| 08:39 EDT | | SRPT | Sarepta eteplirsen demonstrates benefit on walking test in Phase IIb study
Sarepta Therapeutics announced updated data from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne muscular dystrophy, or DMD. Results at 84 weeks showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test. As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at Week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes. Eteplirsen is Sarepta's lead exon-skipping compound in development for the treatment of patients with DMD who have a genotype amenable to skipping of exon 51. |
| |
| 08:05 EDT | | S | Sprint down 3% to $7.10 after DISH ends takeover pursuit
Subscribe for More Information |
|
| 07:59 EDT | | S | Sprint downgraded at Macquarie
As previously reported, Macquarie downgraded Sprint to Neutral from Outperform. The firm recommends taking profits and believes the company is entering a period of heavy investment. Price target is $8. |
|
| 07:13 EDT |  | S | Telecom industry looks to grow through acquisition, Bloomberg reports
Global telecommunications companies are chasing after deals from Kansas to Munich in a quest for revenue growth that could lead to the biggest year for mergers in the industry since at least 2006, reports Bloomberg. Over $80B in telecommunications and cable transactions have already been announced or completed this year Reference Link |
|
| 07:11 EDT | | S | Softbank moves closer to acquiring Sprint, Reuters reports
Subscribe for More Information |
|
| 06:26 EDT | | S | Sprint downgraded to Neutral from Outperform at Macquarie
Subscribe for More Information |
|
| 06:08 EDT | | S | On the Fly: Periodicals Wrap-Up
Subscribe for More Information |
|
| June 18, 2013 |
| 18:36 EDT | | S | DISH issues update on Sprint proposal
Subscribe for More Information |
|
| 11:30 EDT | | S | DISH issues statement on Sprint complaint
DISH Network (DISH) issued the following statement in response to Sprint Nextel's (S) June 17 allegations against DISH and Clearwire (CLWR): “Sprint’s lawsuit is a transparent attempt to divert attention from its failure to deal fairly with Clearwire’s shareholders, as well as to exploit its majority position to block Clearwire’s shareholders from receiving a fair price for their shares. DISH is confident that its superior offer, which has been unanimously recommended by the Clearwire Board, including the majority appointed by Sprint, will be upheld and Clearwire shareholders will be free to realize the 29 percent premium represented by the DISH offer.” |
|
| 05:55 EDT | | S | Stocks with implied volatility movement; S KNDI
Stocks with implied volatility movement; Sprint (S), Kandi Technologies (KNDI) according to IVolatility. |
|
| June 17, 2013 |
| 19:19 EDT | | S | Sprint files suit against DISH, Clearwire over tender offer
Sprint (S) announced that it has filed a complaint in the Delaware Court of Chancery against DISH Network (DISH) and Clearwire (CLWR) asking the court to prevent the consummation of the DISH tender offer for Clearwire. Sprint believes the transaction violates Delaware law and the rights of both Sprint and Clearwire’s other strategic investors under Clearwire’s charter and under the equity hHolders agreement. In addition to seeking to enjoin the tender offer, Sprint’s lawsuit seeks to rescind certain parts of the tender offer agreement and seeks declaratory, injunctive, compensatory and other relief. |
| |
|
|
|
|
